Biomedical Ethics Research Program, Mayo Clinic, Rochester, Minnesota, USA.
Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA.
Cancer Med. 2023 Apr;12(7):8767-8776. doi: 10.1002/cam4.5622. Epub 2023 Jan 16.
Black breast and ovarian cancer patients are underrepresented in clinical cancer trials disproportionate to the prevalence of these cancers in Black females. Historically, lower enrollment has been attributed to individualized factors, including medical mistrust, but more recently structural factors, including systemic racism, have received additional scrutiny. We interviewed Black women with a personal or family history of breast and ovarian cancer to understand their views and experiences related to research participation.
Qualitative interviews were conducted via telephone or video conference and transcribed verbatim. Transcripts were qualitatively analyzed for iterative themes related to the offer and participation in cancer clinical trials and research studies, impact on cancer care, and recommendations to increase enrollment of Black patients.
Sixty-one Black women completed an interview. Participants expressed that Black women are underrepresented in cancer research, and that this negatively impacted their own care. Many cited past historical abuses, including the Tuskegee syphilis trial, as a potential factor for lower enrollment but suggested that lower enrollment was better understood in the context of the entirety of their healthcare experiences, including present-day examples of patient mistreatment or dismissal. Participants suggested that proactive community engagement, transparency, and increased representation of Black research team members were strategies likely to foster trust and bolster research participation.
CONCLUSION(S): Medical mistrust is only a partial factor in the lower participation of Black patients in cancer research. Researchers should implement the strategies identified by our participants to promote diverse enrollment and ensure that Black patients are included in future therapeutic advances.
黑人乳腺癌和卵巢癌患者在癌症临床试验中的代表性不足,与黑人女性中这些癌症的发病率不成比例。从历史上看,参与人数较少的原因可归因于个人因素,包括对医疗的不信任,但最近,包括系统性种族主义在内的结构性因素受到了更多关注。我们采访了有乳腺癌和卵巢癌个人或家族病史的黑人女性,以了解她们对参与癌症临床研究和研究的看法和经验。
通过电话或视频会议进行了定性访谈,并逐字记录下来。对转录本进行了定性分析,以确定与癌症临床试验和研究的提供和参与、对癌症护理的影响以及增加黑人患者参与的建议相关的迭代主题。
61 名黑人女性完成了一次访谈。参与者表示,黑人女性在癌症研究中代表性不足,这对她们自己的护理产生了负面影响。许多人提到过去的历史虐待,包括塔斯基吉梅毒试验,可能是参与率较低的一个潜在因素,但他们认为,在他们全部的医疗保健经验背景下,包括目前患者受到虐待或被忽视的例子,参与率较低更容易理解。参与者建议,积极的社区参与、透明度和增加黑人研究团队成员的代表性是可能促进信任和支持研究参与的策略。
对医疗的不信任只是黑人患者参与癌症研究较少的部分原因。研究人员应实施我们参与者确定的策略,以促进多样化的参与,并确保将黑人患者纳入未来的治疗进展中。